[S-40] Symposium 40 Dyskinesia in Parkinson's Disease: Filling the Bedside-to-Bench Gap

[S-40-4] Future medical treatments for dyskinesias: from bench to bedside

^○M. Angela Cenci^1,2 (1.Lund University, Dept. Experimental Medical Science, Basal Ganglia Pathophysiology, Lund (Sweden), Sweden, 2.Wallenberg Neuroscience Centre, Sweden)

M. Angela Cenci is Professor of Experimental Medical Research at Lund University (Sweden) where she heads the Basal Ganglia Pathophysiology Group. The group’s research addresses the pathophysiology of Parkinson’s disease (PD) and L-DOPA-induced dyskinesia using a multidisciplinary and translational approach. Ongoing projects investigate signaling interactions between dopamine and non-dopaminergic receptors, plasticity in the nigrostriatal system, and the effects of different pharmacological treatments.
Angela graduated in Medicine and specialized in Neurology at the University of Verona (Italy) before obtaining a PhD degree in Neurobiology at Lund University (supervisor: Anders Björklund). She holds a position as Full Professor at Lund University, and she is moreover the Coordinator of Multipark, a strategic research environment focused on Parkinson’s disease and supported by the Swedish Government.